Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study
J Eur Acad Dermatol Venereol
.
2023 Apr 16.
doi: 10.1111/jdv.19117.
Online ahead of print.
Authors
Martina Dragotto
1
,
Eugenio Capalbo
1
,
Alessandra Cartocci
2
,
Flavia Manzo Margiotta
3
,
Alessandra Michelucci
3
,
Elia Rosi
4
,
Federica Ricceri
5
,
Barbara Simoni
6
,
Imma Savarese
7
,
Nicola Milanesi
7
,
Susanna Rossari
8
,
Michela Magnano
8
,
Marco Romanelli
3
,
Pietro Rubegni
1
,
Francesca Prignano
4
,
Antonella Di Cesare
4
,
Salvatore Panduri
3
,
Leonardo Pescitelli
9
,
Emanuele Trovato
1
Affiliations
1
Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy.
2
Department of Medical Biotechnology, University of Siena, Siena, Italy.
3
Department of Dermatology, University of Pisa, Pisa, Italy.
4
Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
5
Unit of Dermatology, San Donato Hospital, Arezzo, Italy.
6
Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy.
7
Department of Dermatology, San Jacopo Hospital, Pistoia, Italy.
8
Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy.
9
Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy.
PMID:
37062048
DOI:
10.1111/jdv.19117
No abstract available
Publication types
Letter